2110 Efficacy outcomes by severity of skin toxicity from ASPECCT: Randomized phase 3 study of panitumumab (pmab) versus cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). (September 2015) - Price, T.; Kim, T.W.; Li, J.; Cascinu, S.; Ruff, P; Suresh, A.S.; Thomas, A.; Tjulandin, S.; Guan, X.; Hoang, T.; Hei, YJ.; Peeters, M.